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Aims Sodium–glucose co-transporter 2 (SGLT2) inhibitors, originally developed as glucose-lowering agents, have been
shown to reduce heart failure hospitalizations in patients with type 2 diabetes without established heart failure, and
in patients with heart failure with and without diabetes. Their role in patients with heart failure with preserved and
mildly reduced ejection fraction remains unknown.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure (DELIVER)
is an international, multicentre, parallel group, event-driven, randomized, double-blind trial in patients with chronic
heart failure and left ventricular ejection fraction (LVEF) >40%, comparing the effect of dapagliflozin 10 mg once
daily, vs. placebo, in addition to standard of care. Patients with or without diabetes, with signs and symptoms of
heart failure, a LVEF >40%, elevation in natriuretic peptides and evidence of structural heart disease are eligible. The
primary endpoint is time-to-first cardiovascular death or worsening heart failure event (heart failure hospitalization
or urgent heart failure visit), and will be assessed in dual primary analyses – the full population and in those with
LVEF <60%. The study is event-driven and will target 1117 primary events. A total of 6263 patients have been
randomized.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusions DELIVER will determine the efficacy and safety of the SGLT2 inhibitor dapagliflozin, added to conventional therapy,
in patients with heart failure and preserved and mildly reduced ejection fraction.
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Introduction
Sodium–glucose co-transporter 2 (SGLT2) inhibitors, originally
developed as glucose-lowering agents, have been shown to reduce
heart failure hospitalizations in patients with type 2 diabetes,
including those without established heart failure.1–3 Moreover, in









.. patients with heart failure and reduced left ventricular ejection
fraction (LVEF ≤40%; HFrEF), including those with and without
type 2 diabetes, both dapagliflozin and empagliflozin reduced
cardiovascular death or heart failure events when added to
standard therapy.4,5 While the mechanisms by which SGLT2
inhibitors improve outcomes in heart failure continue to be
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investigated, they are postulated to include favourable effects
on haemodynamics,6,7 improvement in myocardial energetics
and loading conditions, favourable effects on endothelial func-
tion and inflammation, and slowing of the progression of kidney
disease.8 These effects may collectively underlie observed early
and sustained improvements in filling pressures and ventricular
remodeling.7,9–11
Patients with preserved or mildly reduced ejection fraction
(LVEF >40%) now represent the majority of those with heart fail-
ure, and experience a comparable burden of poor outcomes, such
as death, hospitalizations and symptom burden, as those with LVEF
≤40%; yet suffer from dearth of effective therapies. Therefore,
there is a large and urgent unmet clinical need for efficacious and
safe treatments in this vulnerable patient group. Whether the ben-
efits of SGLT2 inhibitors observed in HFrEF extend to patients
with heart failure and LVEF >40% remains unknown. The benefit of
dapagliflozin in DAPA-HF was similar throughout the ejection frac-
tion spectrum under 40%,12 and data from two trials of a combined
SGLT1 and 2 inhibitor, including one that enrolled recently hospi-
talized patients with diabetes and heart failure, suggest potential
benefits in people with LVEF >40%.13,14 Nevertheless, most heart
failure therapies that have proven effective in patients with LVEF
<40% have been ineffective or significantly less effective in those
with higher LVEF, with several studies showing some attenuation of
benefit as LVEF rose into the normal range.15–18 The heterogene-
ity of the heart failure with preserved ejection fraction (HFpEF)
syndrome has emerged as a key hypothesis underlying the inabil-
ity to identify treatments that reduce its morbidity and mortality.
While HFrEF is also a heterogeneous disorder, it has proven to
respond to therapies in a more homogeneous fashion, with mul-
tiple drug classes associated with improvements in morbidity and
mortality. Many of these benefits appear to extend to heart fail-
ure with mildly reduced LVEF (40–50%, HFmrEF) but not for LVEF
>50%. However, there is reason to believe that SGLT2 inhibitors
may be beneficial in a broad spectrum of HFpEF despite the hetero-
geneous nature of the HFpEF syndrome. Congestion and impaired
renal function are hallmarks of all types of heart failure, includ-
ing HFpEF, and appear to be ameliorated by SGLT2 inhibitors. In
addition, chronic kidney disease is a major risk factor for adverse
outcomes in HFpEF; therefore, it is very possible that by improving
kidney function, SGLT2 inhibitors may have beneficial effects across
the range of LVEF. SGLT2 inhibitors also appear to improve dias-
tolic function, reduce visceral fat (including epicardial fat), reduce
arterial stiffness, and have favourable effects on endothelial func-
tion and inflammation, all of which are important mechanisms of
HFpEF pathogenesis.
The Dapagliflozin Evaluation to Improve the LIVEs of Patients
With PReserved Ejection Fraction Heart Failure (DELIVER) trial
is testing the hypothesis that the SGLT2 inhibitor dapagliflozin
will reduce cardiovascular death and heart failure hospitalization
in patients with heart failure with a LVEF >40% (HFpEF and
HFmrEF ). The design of DELIVER takes into account many of
the learnings from prior trials in heart failure with LVEF >40%
and, along with DAPA-HF, will provide evidence for the efficacy of




















































































.. Trial design and methods
Overall study design and governance
DELIVER is an international, multicentre, parallel group, event-driven,
randomized, double-blind trial in patients with chronic heart failure and
LVEF >40%, comparing the effect of dapagliflozin 10 mg once daily, vs.
placebo, in addition to standard of care. The overall study design is
summarized in Figure 1. DELIVER was designed jointly by the academic
steering committee in conjunction with the sponsor. The conduct of
the trial is overseen by the academic executive committee and the
sponsor in conjunction with national lead investigators. The trial is
registered as ClinicalTrials.gov Identifier: NCT03619213.
Patients
The eligibility criteria for DELIVER are summarized in Table 1. Briefly,
patients with or without diabetes were required to be 40 years of age
or older, with an LVEF >40% (documented by echocardiography or
cardiac magnetic resonance imaging within the last 12 months prior
to enrolment without a subsequent event that might lower LVEF),
evidence of structural heart disease (either left atrial enlargement
or left ventricular hypertrophy), and elevation in natriuretic peptides
[N-terminal pro B-type natriuretic peptide (NT-proBNP) ≥300 pg/mL
(≥600 pg/mL for patients in atrial fibrillation or flutter)]. Both ambula-
tory and hospitalized patients were eligible for enrolment.
Key exclusion criteria included receiving an SGLT2 inhibitor within
4 weeks prior to randomization, or previous intolerance to SGLT2
inhibitors; type 1 diabetes; estimated glomerular filtration rate (eGFR)
<25 mL/min/1.73 m2 at screening; systolic blood pressure ≥160 mmHg
if not on three or more antihypertensive medications, or ≥180 mmHg
regardless of number of medications; probable alternative diagnoses
that might account for the patients’ symptoms (e.g. anaemia, hypothy-
roidism, primary pulmonary hypertension, chronic thromboembolic
disease, requirement for home oxygen therapy); uncorrected primary
valvular disease; known infiltrative heart disease, including known or
suspected amyloid heart disease; myo- or pericarditis; or hypertrophic
cardiomyopathy.
Enrolment in DELIVER began on 27 August 2018 following approval
by appropriate ethics boards, and written informed consent was
obtained from all patients enrolled in DELIVER. The last patient was
randomized on 18 January 2021. Patients are enrolled at 353 sites,
in 20 countries in most major geographic regions (online supplemen-
tary Table S1). The study is being conducted in accordance with Good
Clinical Practice and the Declaration of Helsinki.
Study procedures
Randomization and capping
Following informed consent and screening, and once a patient has
fulfilled the criteria for randomization, all patients were centrally
assigned to randomized investigational product (IP) using an interac-
tive voice/web response system (IxRS). Randomization to IP was per-
formed in balanced blocks to ensure approximate balance between the
treatment groups (1:1). Randomization was stratified in the IxRS sys-
tem based on whether the patient was or was not known to have
type 2 diabetes at the time of randomization (based on either an
established diagnosis or glycated haemoglobin ≥6.5% at enrolment).
Patients were randomized in a 1:1 fashion to dapagliflozin 10 mg or
matching placebo once daily. Several factors, including LVEF value, New
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Study design of DELIVER. PACD, primary analysis censoring date; SCV, study closure visit; SoC, standard of care.
York Heart Association (NYHA) class, ‘subacute’ status (randomized
in-hospital or within 30 days after discharge), and atrial fibrillation were
monitored to enable capped randomization in the IxRS to avoid over
or under-representation of these patient subgroups in each country.
Concomitant medications
Patients are treated according to regional standard of care for all
comorbidities, including diabetes and hypertension, with the exception
of concomitant use of an SGLT2 inhibitor, which is not allowed by
protocol.
Study visits and monitoring
Following randomization, study visits occur at or around days 30, 120,
240, 360, and 480 after randomization, and then every 120 days there-
after. Unscheduled visits can also be performed if considered appropri-
ate in the opinion of the investigator. The full schedule of assessments
is shown in online supplementary Table S2. Treatment adherence is
assessed by asking patients to return all unused investigational prod-
uct and empty packages to the clinic at site visits, and non-compliant
patients are counselled on the importance of taking study medication.
Study outcomes
Primary and other outcomes
The primary objective is to determine whether dapagliflozin is superior
to placebo, when added to standard of care, in reducing the composite
of worsening heart failure episodes (either unplanned hospitalization
or urgent heart failure visit requiring intravenous therapy but not
requiring a hospital admission) or cardiovascular death, analysed as
time-to-first event (Table 2). The primary endpoint will be assessed in
both the full population and in patients with LVEF <60% (dual primary
analyses; see statistical analysis below). Secondary objectives are to
determine whether dapagliflozin is superior to placebo in reducing
the total number of heart failure events (hospitalization for heart
failure or urgent heart failure visit) and cardiovascular death in (i) the
full study population, and (ii) the sub-population with LVEF <60%; in
improving patient-reported outcomes measured by the Kansas City























































. in reducing cardiovascular death; in reducing all-cause mortality. Several
exploratory endpoints will also be assessed (online supplementary
Table S3): whether dapagliflozin compared with placebo will have an
effect on slope of eGFR (assessed as between randomization and 1
and 2 years, respectively, and between a post-randomization time point
and 1 and 2 years, respectively); and assessment of benefits within
the sub-domains of the KCCQ, stratified by type 2 diabetes status at
randomization, and adjusted for the baseline value.
Endpoint adjudication
An independent Cardiovascular Endpoint Committee (CEC), blinded
to treatment assignment, is categorizing all deaths and adjudicating
non-fatal cardiovascular events as possible endpoints based on the
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
developed by the Standardized Data Collection for Cardiovascular
Trials Initiative.19 All potential episodes of possible ketoacidosis are
also being adjudicated.
Accommodation for COVID-19
As the COVID-19 pandemic evolved during the course of the study, the
trial has made several adaptations to ensure the quality and integrity
of the data collected. These included as necessary conversion of
in-person visits to phone and virtual visits, remote data collection
for patient-reported outcomes, reporting of all COVID-19 related
adverse events and adjudication of COVID-19 related hospitalizations
and deaths.
Statistical considerations
Sample size considerations and statistical analyses
The primary objective of the study is to determine the superiority
of dapagliflozin vs. placebo added to standard of care in reducing
the composite of worsening heart failure events (hospitalization for
heart failure or urgent heart failure visit) or cardiovascular death,
measured as time-to-first occurrence of any of the components of
the composite. Two hypotheses will be tested simultaneously (i.e. dual
primary analyses) for the primary analysis: (i) in the full population
and (ii) in the population with LVEF <60%. Alpha will be allocated
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Eligibility criteria for DELIVER
Inclusion criteria
1. Ability to give written informed consent.
2. Men and women age ≥40 years.
3. Documented diagnosis of symptomatic heart failure (NYHA class II–IV) at enrolment, and a medical history of typical symptoms/signs of
heart failure ≥6 weeks before enrolment with at least intermittent need for diuretic treatment (requiring recurrent intermittent dosing).
4. LVEF >40% and evidence of structural heart disease (i.e. left ventricular hypertrophy or left atrial enlargement) documented by the most
recent echocardiogram, and/or cardiac magnetic resonance within the last 12 months prior to enrolment. For patients with prior acute
cardiac events or procedures that may reduce LVEF, e.g. as defined in exclusion criterion, qualifying cardiac imaging assessment at least
12 weeks following the procedure/event is required. Structural heart disease will be defined as:
• LA enlargement with at least one of the following: LA width (diameter) ≥3.8 cm or LA length≥ 5.0 cm, or LA area ≥20 cm, or LA volume
≥55 mL or LA volume index ≥29 mL/m.
• Left ventricular hypertrophy with septal thickness or posterior wall thickness≥1.1 cm.
5. NT-proBNP ≥300 pg/mL at Visit 1 for patients without ongoing atrial fibrillation/flutter. If ongoing atrial fibrillation/flutter at Visit 1,
NT-proBNP must be ≥600 pg/mL.
6. Patients may be ambulatory, or hospitalized; patients must be off intravenous heart failure therapy (including diuretics) for at least 12 h prior
to enrolment and 24 h prior to randomization.
Exclusion criteria
1. Receiving therapy with an SGLT2 inhibitor within 4 weeks prior to randomization or previous intolerance to an SGLT2 inhibitor.
2. Type 1 diabetes mellitus.
3. eGFR < 25 mL/min/1.73 m2 (CKD-EPI formula) at Visit 1.
4. Systolic blood pressure <95 mmHg on two consecutive measurements at 5 min intervals, at Visit 1 or at Visit 2.
5. Systolic blood pressure ≥160 mmHg if not on treatment with ≥3 blood pressure lowering medications or ≥180 mmHg irrespective of
treatments, on two consecutive measurements at 5 min intervals, at Visit 1 or at Visit 2.
6. Myocardial infarction, unstable angina, coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting),
ablation of atrial flutter/fibrillation, valve repair/replacement within 12 weeks prior to enrolment. Before enrolment, these patients must have
their qualifying echocardiography and/or cardiac magnetic resonance examination at least 12 weeks after the event.
7. Planned coronary revascularization, ablation of atrial flutter/fibrillation and valve repair/replacement.
8. Stroke or transient ischaemic attack within 12 weeks prior to enrolment.
9. Probable alternative or concomitant diagnoses which in the opinion of the investigator could account for the patient’s heart failure symptoms
and signs (e.g. anaemia, hypothyroidism).
10. Body mass index >50 kg/m2.
11. Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including COPD (i.e. requiring home oxygen,
chronic nebulizer therapy or chronic oral steroid therapy, or hospitalization for exacerbation of COPD requiring ventilatory assistance within
12 months prior to enrolment).
12. Previous cardiac transplantation, or complex congenital heart disease. Planned cardiac resynchronization therapy.
13. Heart failure due to any of the following: known infiltrative cardiomyopathy (e.g. amyloid, sarcoid, lymphoma, endomyocardial fibrosis), active
myocarditis, constrictive pericarditis, cardiac tamponade, known genetic hypertrophic cardiomyopathy or obstructive hypertrophic
cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy/dysplasia, or uncorrected primary valvular disease.
14. A life expectancy of less than 2 years due to any non-cardiovascular condition, based on investigator’s clinical judgement.
15. Inability of the patient, in the opinion of the investigator, to understand and/or comply with study medications, procedures and/or follow-up
or any conditions that, in the opinion of the investigator, may render the patient unable to complete the study.
16. Active malignancy requiring treatment (with the exception of basal cell or squamous cell carcinomas of the skin).
17. Acute or chronic liver disease with severe impairment of liver function (e.g. ascites, oesophageal varices, coagulopathy).
18. Women of child-bearing potential (i.e. those who are not chemically or surgically sterilized or post-menopausal) not willing to use a medically
accepted method of contraception considered reliable in the judgement of the investigator or who have a positive pregnancy test at
randomisation or who are breast-feeding.
19. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca personnel and/or personnel at the study site).
20. Previous randomization in the present study.
21. Participation in another clinical study with an investigational product or device during the last month prior to enrolment.
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LA, left atrial; LVEF,
left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; SGLT2, sodium–glucose co-transporter 2.
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Table 2 Primary and secondary study objectives and endpoints
Study objective Corresponding endpoint
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Primary objective
To determine whether dapagliflozin is superior to placebo, when added to
standard of care, in reducing the composite of CV death and HF events
(hospitalization for HF or urgent HF visit) in patients with HF and preserved
systolic function in (i) the full study population, and (ii) the sub-population with
LVEF <60%
Time to the first occurrencea of any of the components of this
composite:
1. CV death
2. Hospitalization for HF
3. Urgent HF visit (e.g. emergency department or
outpatient visit)
Secondary objectives
To determine whether dapagliflozin is superior to placebo in reducing the total
number of HF events (hospitalization for HF or urgent HF visit) and CV death
in (i) the full study population, and (ii) the sub-population with LVEF <60%
Total numberb of HF events (first and recurrent) and CV death
To determine whether dapagliflozin is superior to placebo in improving
patient-reported outcomes measured by KCCQ
Change from baseline in the total symptom score of the KCCQ
at 8 months
To determine whether dapagliflozin is superior to placebo in reducing CV death Time to the occurrence of CV death
To determine whether dapagliflozin is superior to placebo in reducing all-cause
mortality
Time to the occurrence of death from any cause
Safety objective
To evaluate the safety and tolerability of dapagliflozin compared to placebo in
patients with HFpEF
Serious AEs, AEs leading to treatment discontinuation,
amputations, AEs leading to amputation and potential risk
factor for AEs leading to amputations affecting the lower limbs
AE, adverse event; CV, cardiovascular; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF, left
ventricular ejection fraction.
aAnalysis using Cox regression stratified by type 2 diabetes at baseline.
bAnalysis performed using the semi-parametric method of Lin, Wei, Yang and Ying (LWYY).
to each primary test to ensure control of the overall type I error
rate, with the exact alpha split determined prior to the interim
analysis. The study protocol was modified on 12 November 2020
introducing the current dual primary analysis, in which cardiovascular
death or worsening heart failure events will be evaluated in both the
full study population (as original primary analysis) and the population
with LVEF <60%. For the original analysis, 844 primary events were
targeted to provide 90% power for the primary endpoint. To allow
for testing the dual primary hypotheses, the target number of patients
with a primary endpoint was subsequently increased to 1117 to
provide adequate statistical power for each of the two dual primary
analyses. The original targeted sample size of 4700 patients was
increased to 6100 based on blinded monitoring of event accrual and
the increase in target number of primary events. It is anticipated
that at least 70% of the primary endpoint events (i.e. approximately
780 events) will be contributed by the LVEF <60% sub-population.
A total sample size of 6100 patients is anticipated to provide 93%
power to detect a 20% relative risk reduction for the primary endpoint
for a two-sided nominal alpha of 0.024. Recruitment was completed
on 21 January 2021 with a total of 6263 patients randomized. The
anticipated median follow-up will be 27 months. All analyses will be
according to the intention-to-treat principle. Full details of all analyses
will be provided in a statistical analysis plan prior to unblinding
of the trial.
Methods of statistical analysis
A closed testing procedure including a pre-specified hierarchical order-
ing of the primary and secondary endpoints will be utilized. Statistical










































Figure 2 Hierarchical testing scheme for primary and
secondary endpoints. CV, cardiovascular; HF, heart failure;
KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire total
symptom score; LVEF, left ventricular ejection fraction.
of the endpoints and populations as specified in Figure 2. Following the
dual assessment of the primary endpoint (time-to-first event for the
composite endpoint of cardiovascular death and worsening heart fail-
ure event) in both the full population, and in those with LVEF <60%,
subsequent testing will occur in two parallel paths as shown. If the null
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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hypothesis is rejected in the full population for the primary analysis
analysed using a Cox proportional hazards model, then testing will
occur for recurrent events in the full population using the LWYY
method, followed by comparison of change from baseline to 8 months
in the KCCQ-TSS using the rank ANCOVA method (to test difference
in distribution) and the win ratio test (to estimate treatment effect),
followed by comparison of time to cardiovascular death, followed by
time to all-cause death in Cox regression analyses. If the null hypothesis
is rejected in the sub-population with LVEF <60%, total and recurrent
events will be assessed first in the sub-population and subsequently in
the full population, with allocation of alpha for each successive positive
test. If all null hypotheses are rejected within a particular branch, the
alpha is recycled to the other branch where the hypotheses will be
tested with full alpha.
Analysis of secondary endpoints
Sub-domains of the KCCQ-TSS (symptom frequency and symptom
burden) and overall symptom score (OSS) will be analysed with rank
ANCOVA and win ratio in the same manner as for TSS. Descriptive
statistics of scores and changes from baseline will be presented for all
scores.
Subgroup analyses
The following pre-specified sub-groups of interest will be assessed for
the dual primary endpoints: age at vs. below, vs. above, the median; sex;
race; geographic region; NYHA class (II vs. III/IV) at enrolment; LVEF
category at enrolment (41–49% vs. 50–59%, and ≥60%); NT-proBNP
at enrolment (at or below, vs. above the median); randomization in
hospital or within 30 days of discharge vs. others; eGFR at enrolment
(<60 vs. ≥60 mL/min/1.73 m2); body mass index at enrolment (<30 vs.
≥30 kg/m2); diabetes status at enrolment; systolic blood pressure at
randomization (at or below vs. above the median); atrial fibrillation or
flutter vs. other rhythms at enrolment. The effect of treatment will also
be assessed as a function of LVEF and glycated haemoglobin examined
as continuous variables.
In addition to the within trial analyses, we have pre-specified prior
to the unblinding of DAPA-HF that data from both dapagliflozin heart
failure trials, DAPA-HF and DELIVER, will be pooled and assessed in
a patient-level meta-analysis to assess the effect of dapagliflozin across
the full spectrum of heart failure.
Data monitoring committee and interim analysis
A data safety monitoring committee is overseeing the trial and will
undertake one interim analysis when approximately 67% of the tar-
get number of primary endpoints are reached, where the primary
composite endpoint will be tested in the full study population at a sig-
nificance level of 0.2%. If the null hypothesis is rejected, superiority of
dapagliflozin to placebo on cardiovascular death will be tested at the
same significance level.
Discussion
Heart failure with LVEF >40% (HFpEF and HFmrEF) represents
a large group of patients without clear guideline-directed therapy
with great unmet need. SGLT2 inhibitors are the first treat-
ments being tested for heart failure with LVEF >40% that are
not neurohormonal modulators. This might give this class an



















































































.. safety. While vasodilator-type agents clearly benefit patients with
HFrEF, peripheral vasodilatation may provide less benefit and may
be associated with more hypotension in patients with higher LVEF.
On the other hand, several of the mechanisms by which SGLT2
inhibitors have been postulated to be beneficial in HFrEF would
be expected to be similarly beneficial in patients with heart failure
and higher LVEF, such as improvements in filling pressures and
ventricular remodelling,9,10,11 and kidney benefits.8 Furthermore,
SGLT2 inhibitors have been shown to improve diastolic function
in patients with diabetes and LVEF ≥50%,20 reduce obesity and
attenuate epicardial fat accumulation or its secretion of delete-
rious adipokines,21 as well as improve endothelial function and
reduce inflammation – mechanistic factors particularly asso-
ciated with heart failure in the setting of higher LVEF. Indeed,
we observed no heterogeneity in the treatment response to
dapagliflozin based on LVEF in patients with HFrEF, and more
recent data from SOLOIST-WHF and SCORED suggest that
therapy with sotagliflozin benefited recently hospitalized patients
with HFpEF.13,14
Clinical trials in HFpEF have been challenging for several rea-
sons, including difficulties in ensuring enrolment of the appropriate
patients who truly have the clinical syndrome of heart failure,
and because of the phenotypic, biological and likely therapeutic
heterogeneity of the disease. All prior outcomes trials in this
population to date have fallen short of demonstrating a convincing
therapeutic benefit on their primary endpoint. Most recently,
the PARAGON-HF trial, which compared sacubitril/valsartan to
valsartan, narrowly missed statistical significance for the primary
endpoint of total heart failure hospitalizations and cardiovascular
death.17 However, the data from PARAGON-HF suggested that
patients with LVEF at or below the pre-specified median of 57%
had a greater treatment benefit than those with higher LVEF,
and this finding was confirmed when LVEF was assessed contin-
uously. This pattern of declining benefit with increasing LVEF has
also been observed in two other clinical trials, TOPCAT which
compared spironolactone to placebo, and CHARM-Preserved
which compared candesartan to placebo.15,16 Whether declining
benefit with increasing LVEF is unique to these prior treatment
approaches that utilized neurohormonal modulators or is in fact
a general characteristic of patients with heart failure with LVEF
>40%, is unknown. That prior HFpEF trials have shown that
treatment effect with a broad range of therapies declined with
increasing LVEF provided the rationale for the dual primary analysis
incorporated into DELIVER.
The design of DELIVER is unique in several ways. First, DELIVER
was designed to complement DAPA-HF which assessed the efficacy
of dapagliflozin in patients with HFrEF. The results of both studies
will be pooled to assess the effects of dapagliflozin across the
spectrum of ejection fraction. The entry criteria reflected the
contemporary view that patients with heart failure should have
both elevation of natriuretic peptides and evidence of structural
heart disease (Table 3).17,22–26 In contrast to the PARAGON-HF
and TOPCAT trials which were restricted to patients with LVEF
≥45% who had never had LVEF <40%, DELIVER is enrolling
patients with LVEF >40%, and is allowing patients with previous
LVEF ≤40%. This will allow for a wide range of patients with
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































.. mildly reduced ejection fraction. Second, the primary outcome
will incorporate both heart failure hospitalizations and urgent
heart failure visits. Urgent heart failure visits, requiring evidence
of intravenous diuretic therapy, have been a component of the
primary endpoint of several prior heart failure trials, including
DAPA-HF, and have proven to be both prognostically similar
to heart failure hospitalizations and similarly discriminative of
treatment effects in several trials.27,28 Moreover, with increasing
needs for outpatient management of worsening heart failure due to
changes in healthcare care delivery and patient preferences, urgent
heart failure visits are logical for inclusion in the primary endpoint.
While prior studies in this population with neurohormonal
modulators have noted decline in efficacy with increasing LVEF,
the unique mechanism of action of SGLT2 inhibitors and data
from DECLARE-TIMI 58 and DAPA-CKD suggest the potential for
beneficial effects across the spectrum of ejection fraction.3,29
Nevertheless, the incorporation in DELIVER of dual-primary
analyses with appropriate protection against multiple comparisons
allows for the possibility of differential effect by LVEF, while pre-
serving adequate statistical power to assess both the overall study
population.
While the primary outcomes in DELIVER are based on
time-to-first event for cardiovascular death or heart failure event,
which includes both heart failure hospitalizations and urgent heart
failure visits, testing hierarchy for secondary endpoints allows for
assessment of first and recurrent events in both the sub-population
of patients with LVEF <60% and then the full population (if the
null hypothesis for the sub-population is rejected) for the primary
outcome. Recurrent events have provided more statistical power
in some, but not all, trials in heart failure,30,31 and may be especially
helpful in trials of HFpEF where there are relatively few cardiovas-
cular deaths relative to heart failure events. Furthermore, if the
null hypotheses are rejected for each of these endpoints (primary
for LVEF <60%, recurrent events for LVEF <60%, and recurrent
events for the full population), the full population can then be
re-tested with full alpha. This unique approach takes into account
the uncertainty regarding which population will have the greatest
benefit and which testing method (time to first vs. recurrent
events) would be most successful in this population and with
this therapy. The specific order of the hierarchy, with assessment
of KCCQ-TSS above cardiovascular and all-cause mortality, is
based on the importance of the endpoints to the population, the
relatively low number of deaths in this population, and the low
overall likelihood of benefit for fatal endpoints.
There are both similarities and differences between DELIVER
and EMPEROR-Preserved,32 the other ongoing SGLT2 inhibitor
outcome trial in a similar population. Both studies have similar
entry criteria, including patients with heart failure and LVEF >40%,
requirement for elevation in natriuretic peptides, and evidence
for structural heart disease (although patients could be enrolled
in EMPEROR-Preserved without evidence of structural heart dis-
ease if they had a heart failure hospitalization within 12 months).
The primary differences are that the dual primary endpoints in
DELIVER allow for the possibility of testing the primary effi-
cacy hypothesis in both the full population and in the subset of
patients with LVEF <60%, an innovation that takes into account the
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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results of prior trials. In addition, other trials, including EMPUSLE
(NCT04157751)33 and DAPA ACT HF-TIMI 68 (NCT04363697)
are testing SGLT2 inhibitors in acute and stabilized hospitalized
heart failure patients.
In summary, DELIVER will determine whether dapagliflozin com-
pared with placebo will reduce the risk of cardiovascular death
or worsening heart failure in patients with HFpEF or HFmrEF.
DELIVER will provide complementary information to DAPA-HF,
which studied the adjacent population with HFrEF. The design of
DELIVER takes into account the collective experience from prior
trials in a patient population with great unmet need.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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